Lyra Therapeutics, Inc.
LYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $672 | $13,033 | $4,747 | $2,831 |
| - Cash | $41 | $22 | $33 | $46 |
| + Debt | $34 | $27 | $4 | $1 |
| Enterprise Value | $666 | $13,038 | $4,719 | $2,787 |
| Revenue | $2 | $2 | $1 | $0 |
| % Growth | -1.5% | 14.3% | 378.2% | – |
| Gross Profit | $2 | $2 | $1 | -$29 |
| % Margin | 100% | 100% | 100% | -10,318.9% |
| EBITDA | -$60 | -$65 | -$54 | -$43 |
| % Margin | -3,928.4% | -4,188.1% | -3,956.2% | -14,952.3% |
| Net Income | -$93 | -$63 | -$55 | -$44 |
| % Margin | -6,090.9% | -4,023.1% | -4,055.6% | -15,267.7% |
| EPS Diluted | -1.43 | -1.26 | -1.83 | -3.35 |
| % Growth | -13.5% | 31.1% | 45.4% | – |
| Operating Cash Flow | -$70 | -$63 | -$43 | -$26 |
| Capital Expenditures | -$2 | -$1 | -$0 | -$3 |
| Free Cash Flow | -$72 | -$64 | -$44 | -$29 |